Avalo Therapeutics

Yahoo Finance • last year

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Successfully eliminated $35 million debt paving the way for future growth and innovation Divested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo’s promising immunology assetsDisclosed... Full story

Yahoo Finance • last year

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

WAYNE, Pa. and ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- In a major achievement, Avalo Therapeutics (Nasdaq: AVTX) proudly announces the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporat... Full story

Yahoo Finance • last year

Avalo Enters into Agreement to Divest AVTX-800 Series

WAYNE, Pa. and ROCKVILLE, Md. , Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Therapeutics, LLC (AUG) to sell its rights... Full story

Yahoo Finance • last year

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the H.C. Wainwright 25... Full story

Yahoo Finance • last year

Avalo to Participate in SVB Securities Therapeutics Forum

WAYNE, Pa. and ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will participate in the SVB Securities... Full story

Yahoo Finance • last year

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

AVTX-002 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo, although positive trends were observed among a sub-population of patients with elevated baseline serum LIGHT levels AVTX-002 sig... Full story

Yahoo Finance • 2 years ago

Avalo to Present at ATS 2023 Respiratory Innovation Summit

WAYNE, Pa. and ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will attend and present at the ATS 2023... Full story

Yahoo Finance • 2 years ago

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the 2023 RBC Capital Mar... Full story

Yahoo Finance • 2 years ago

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

Topline data expected in the second quarter of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA) Disclosed cash of approximately $16.7 million as of March 31, 2023 WAYNE, Pa. and ROCKVILLE, Md., May 04, 2023... Full story

Yahoo Finance • 2 years ago

Avalo Reports 2022 Financial Results and Provides Business Updates

Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline data expected in the second quarter of 2023 Disclosed cash of approximately $13 million as of December 31, 2022, non-inclusive of the Febr... Full story

Yahoo Finance • 2 years ago

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., March 07, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at Oppenheimer's 33rd Annua... Full story

Yahoo Finance • 2 years ago

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

WAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (Avalo) announced today the pricing of an underwritten public offering of 3,770,000 shares of its common stock and warrants to purch... Full story

Yahoo Finance • 2 years ago

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

WAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”) announced today that it has commenced a proposed underwritten public offering of shares of its common stock and warrants t... Full story

Yahoo Finance • 2 years ago

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

Topline data expected in the second quarter of 2023 WAYNE, Pa. and ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that it completed enrollment of the 80 patients targeted for t... Full story

Yahoo Finance • 2 years ago

Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million

WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement to sell its economic rights to future payments for previously out-licensed ass... Full story

Yahoo Finance • 2 years ago

Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage

Strategy focused on LIGHT-signaling network targets WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) announced today that its human B and T Lymphocyte Attenuator (BTLA) agonist f... Full story

Yahoo Finance • 2 years ago

Avalo Therapeutics Announces Board Changes

Avalo Therapeutics WAYNE, Pa. and ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that on August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the inves... Full story

Yahoo Finance • 2 years ago

Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates

Avalo Therapeutics Transferred anti-IL 18 monoclonal antibody product (AVTX-007) to Apollo Therapeutics in July with the approximate $15 million of upfront payment received in August Dosed first patient in the Phase 2 PEAK Trial of its a... Full story

Yahoo Finance • 2 years ago

Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics

Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments.Apollo to lead continued clinical development of AVTX-007, currently in Phase 1b ROCKVILLE, Md. and CAMBRIDGE, United Kingdom, Aug. 01... Full story

Yahoo Finance • 2 years ago

Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split

WAYNE, Pa. and ROCKVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a one-for-twelve reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:0... Full story